Your browser doesn't support javascript.
loading
Drug repurposing: progress, challenges and recommendations.
Pushpakom, Sudeep; Iorio, Francesco; Eyers, Patrick A; Escott, K Jane; Hopper, Shirley; Wells, Andrew; Doig, Andrew; Guilliams, Tim; Latimer, Joanna; McNamee, Christine; Norris, Alan; Sanseau, Philippe; Cavalla, David; Pirmohamed, Munir.
Afiliação
  • Pushpakom S; MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK.
  • Iorio F; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK.
  • Eyers PA; Department of Biochemistry, Institute of Integrative Biology, University of Liverpool, Liverpool, UK.
  • Escott KJ; Emerging Innovations Unit, Scientific Partnering and Alliances, IMED Biotech Unit, AstraZeneca, Cambridge, UK.
  • Hopper S; Licensing Division, Medicines and Healthcare Products Regulatory Agency (MHRA), London, UK.
  • Wells A; Harrison Goddard Foote, Patent and Trademark Attorneys, Manchester, UK.
  • Doig A; Manchester Institute of Biotechnology and Department of Chemistry, Faculty of Science and Engineering, The University of Manchester, Manchester, UK.
  • Guilliams T; Healx Ltd., St John's Innovation Centre, Cambridge, UK.
  • Latimer J; Medical Research Council, London, UK.
  • McNamee C; MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK.
  • Norris A; MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK.
  • Sanseau P; Medicines Research Centre, Target Sciences, GlaxoSmithKline R&D, Stevenage, Hertfordshire, UK.
  • Cavalla D; Numedicus Ltd, Cambridge, UK.
  • Pirmohamed M; MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK.
Nat Rev Drug Discov ; 18(1): 41-58, 2019 01.
Article em En | MEDLINE | ID: mdl-30310233
ABSTRACT
Given the high attrition rates, substantial costs and slow pace of new drug discovery and development, repurposing of 'old' drugs to treat both common and rare diseases is increasingly becoming an attractive proposition because it involves the use of de-risked compounds, with potentially lower overall development costs and shorter development timelines. Various data-driven and experimental approaches have been suggested for the identification of repurposable drug candidates; however, there are also major technological and regulatory challenges that need to be addressed. In this Review, we present approaches used for drug repurposing (also known as drug repositioning), discuss the challenges faced by the repurposing community and recommend innovative ways by which these challenges could be addressed to help realize the full potential of drug repurposing.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Indústria Farmacêutica / Descoberta de Drogas / Reposicionamento de Medicamentos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Nat Rev Drug Discov Assunto da revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Indústria Farmacêutica / Descoberta de Drogas / Reposicionamento de Medicamentos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Nat Rev Drug Discov Assunto da revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Reino Unido